HUTCHMED received conditional NMPA approval for ATLED, supported by a 42.5% objective response rate in pretreated advanced ICC patients with FGFR2 fusions or rearrangements. For investors, the decision creates a China-marketed treatment while HUTCHMED retains worldwide rights, with a Phase IIIb confirmatory cohort already initiated.

Key Highlights

  • ATLED will be sold in China as fanregratinib for eligible adult patients with advanced, metastatic or unresectable ICC.
  • Median overall survival reached 16.6 months, while disease control reached 83.9% in the Phase II registration cohort.
  • HUTCHMED retains worldwide rights to fanregratinib and began the confirmatory Phase IIIb cohort in January 2026.

HUTCHMED (China) Limited received conditional approval from China’s National Medical Products Administration for ATLED, its oral fanregratinib treatment for a defined group of adult intrahepatic cholangiocarcinoma patients. The decision covers advanced, metastatic or unresectable disease with FGFR2 fusions or rearrangements after prior systemic therapy. ATLED will be marketed in China under that Brand name, giving pretreated advanced ICC patients another treatment option.

The approval was supported by a Phase II registration cohort in a key Phase II/IIIb trial conducted in China. The study reported an independent-review objective response rate of 42.5% among pretreated advanced ICC patients with FGFR2 fusions or rearrangements.

Fanregratinib, also known as HMPL-453, is an oral selective inhibitor targeting FGFR1, FGFR2 and FGFR3. The China approval applies specifically to adult patients whose advanced ICC carries the stated FGFR2 genetic alterations and whose disease has previously received systemic therapy.

HUTCHMED said the treatment is intended to provide a precision-medicine option in this setting. The company retains all rights to fanregratinib worldwide. ATLED is the brand under which the treatment will be marketed in China.

The key study was single-arm, multi-center and open-label. Its Phase II registration cohort met its primary endpoint, with the response rate supported by a 95% confidence interval of 30.0% to 53.6%.

Clinical Data Support Conditional Decision

The trial’s secondary measures showed additional activity.

Median duration of response was 6.9 months, with a 95% confidence interval of 5.6 to 8.5 months. The disease control rate was 83.9%, with a 95% confidence interval of 74.5% to 90.9%.

Median progression-free survival was 6.9 months, based on a 95% confidence interval of 4.1 to 8.2 months. Median overall survival reached 16.6 months, with a 95% confidence interval of 12.4 to 16.6 months.

The data form the clinical basis for the conditional NMPA decision.

Phase IIIb Confirmation Underway

The Phase IIIb portion of the trial is intended to confirm ATLED’s clinical benefits and safety in the same treatment setting. Enrollment in that confirmatory cohort began in January 2026.

HUTCHMED said it plans to bring ATLED to patients rapidly in China. Further clinical development and commercialization remain subject to risks involving enrollment, study requirements, safety issues, regulatory approval in other jurisdictions and commercial acceptance.

The company also identified risks relating to whether fanregratinib studies meet their primary or secondary endpoints and whether HUTCHMED can fund, implement and complete its further development and commercialization plans.

Source(s)

  • https://www.sec.gov/Archives/edgar/data/1648257/000164825726000053/hcm-20260828x6k.htm